Literature DB >> 19932969

The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone.

Jared R Mays1, Stephanie A Hill, Justin T Moyers, Brian S J Blagg.   

Abstract

The natural products novobiocin and derrubone have both demonstrated Hsp90 inhibition and structure-activity relationships have been established for each scaffold. Given these compounds share several key structural features, we hypothesized that incorporation of elements from each could provide insight to structural features important for Hsp90 inhibition. Thus, chimeric analogues of novobiocin and derrubone were constructed and evaluated. These studies confirmed that the functionality present at the 3-position of the isoflavone plays a critical role in determining Hsp90 inhibition and suggests that the bicyclic ring system present in both novobiocin and derrubone do not share similar modes of binding. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932969      PMCID: PMC2818389          DOI: 10.1016/j.bmc.2009.10.061

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  34 in total

Review 1.  Hsp90: chaperoning signal transduction.

Authors:  K Richter; J Buchner
Journal:  J Cell Physiol       Date:  2001-09       Impact factor: 6.384

2.  Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.

Authors:  M G Marcu; T W Schulte; L Neckers
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 3.  Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.

Authors:  William B Pratt; David O Toft
Journal:  Exp Biol Med (Maywood)       Date:  2003-02

Review 4.  Heat-shock protein 90, a chaperone for folding and regulation.

Authors:  D Picard
Journal:  Cell Mol Life Sci       Date:  2002-10       Impact factor: 9.261

5.  17AAG: low target binding affinity and potent cell activity--finding an explanation.

Authors:  Gabriela Chiosis; Henri Huezo; Neal Rosen; Edward Mimnaugh; Luke Whitesell; Len Neckers
Journal:  Mol Cancer Ther       Date:  2003-02       Impact factor: 6.261

Review 6.  Hsp90 inhibitors as novel cancer chemotherapeutic agents.

Authors:  Len Neckers
Journal:  Trends Mol Med       Date:  2002       Impact factor: 11.951

Review 7.  HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Authors:  Alison Maloney; Paul Workman
Journal:  Expert Opin Biol Ther       Date:  2002-01       Impact factor: 4.388

Review 8.  Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.

Authors:  M V Blagosklonny
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

Review 9.  The Hsp90 chaperone complex as a novel target for cancer therapy.

Authors:  M P Goetz; D O Toft; M M Ames; C Erlichman
Journal:  Ann Oncol       Date:  2003-08       Impact factor: 32.976

10.  The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity.

Authors:  Alison C Donnelly; Jared R Mays; Joseph A Burlison; John T Nelson; George Vielhauer; Jeffrey Holzbeierlein; Brian S J Blagg
Journal:  J Org Chem       Date:  2008-10-22       Impact factor: 4.354

View more
  5 in total

Review 1.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

2.  Application of silver N-heterocyclic carbene complexes in O-glycosidation reactions.

Authors:  Ian J Talisman; Vineet Kumar; Jeffrey R Deschamps; Mark Frisch; Sanjay V Malhotra
Journal:  Carbohydr Res       Date:  2011-08-02       Impact factor: 2.104

3.  Differentiating Antiproliferative and Chemopreventive Modes of Activity for Electron-Deficient Aryl Isothiocyanates against Human MCF-7 Cells.

Authors:  Ruthellen H Anderson; Cody J Lensing; Benjamin J Forred; Michael W Amolins; Cassandra L Aegerter; Peter F Vitiello; Jared R Mays
Journal:  ChemMedChem       Date:  2018-07-20       Impact factor: 3.466

4.  Synthesis and Evaluation of Functionalized Aryl and Biaryl Isothiocyanates against Human MCF-7 Cells.

Authors:  Claire C Fanta; Kaitlyn J Tlusty; Sarah E Pauley; Amanda L Johnson; Genevieve A Benjamin; Taylor K Yseth; Michaela M Bunde; Paul T Pierce; Shirley Wang; Peter F Vitiello; Jared R Mays
Journal:  ChemMedChem       Date:  2022-06-09       Impact factor: 3.540

Review 5.  The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.

Authors:  Michael A Serwetnyk; Brian S J Blagg
Journal:  Acta Pharm Sin B       Date:  2020-11-24       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.